Therapy-induced senescence in cancer

Journal of the National Cancer Institute

Volumn 102, Issue 20, 2010, Pages 1536-1546

  Ewald, Jonathan A ^a   Desotelle, Joshua A ^a,b   Wilding, George ^a,c   Jarrard, David F ^a,b,c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [[9 CHLORO 7 (2,6 DIFLUOROPHENYL) 5H PYRIMIDO[5,4 D][2]BENZAZEPIN 2 YL]AMINO]BENZOIC ACID; ANTINEOPLASTIC AGENT; AURORA A KINASE; BIOCHEMICAL MARKER; BLEOMYCIN; CAMPTOTHECIN; CARBOPLATIN; CHEMOKINE RECEPTOR CXCR2; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLOPHOSPHAMIDE; DIAZIQUONE; DOCETAXEL; DOXORUBICIN; EPIGALLOCATECHIN GALLATE; ETOPOSIDE; FLUOROURACIL; HYDROXYUREA; INTERLEUKIN 6; K 858; MESSENGER RNA; MEVINOLIN; MITOGEN ACTIVATED PROTEIN KINASE P38; MLN 4924; PEP 005; PEP 008; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; PROTEIN P63; PROTEIN P73; RAF PROTEIN; RESVERATROL; RETINOBLASTOMA PROTEIN; SOMATOMEDIN BINDING PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CANCER CELL; CANCER RADIOTHERAPY; CANCER THERAPY; CELL IMMORTALIZATION; CELL TRANSFORMATION; CYTOSTASIS; GENE EXPRESSION; HUMAN; MORPHOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SENESCENCE; STRESS; TREATMENT RESPONSE; TUMOR IMMUNITY; ANIMAL; APOPTOSIS; CELL AGING; CELL PROLIFERATION; DRUG EFFECTS; GENETICS; NEOPLASMS; OXIDATIVE STRESS; PATHOLOGY; QUALITY OF LIFE; TIME;

ANIMALS; APOPTOSIS; CELL AGING; CELL PROLIFERATION; HUMANS; NEOPLASMS; OXIDATIVE STRESS; QUALITY OF LIFE; TIME FACTORS;

EID: 77958590185     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq364     Document Type: Review

References (98)

1. Desai AA, Stadler WM. Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents. Curr Urol Rep. 2006;7(1): 16-22.
2. Martin L, Schilder RJ. Novel non-cytotoxic therapy in ovarian cancer: current status and future prospects. J Natl Compr Canc Netw. 2006; 4(9):955-966.
3. Winquist E, Waldron T, Berry S, Ernst DS, Hotte S, Lukka H. Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care's Genitourinary Cancer Disease Site Group. BMC Cancer. 2006;6:112.
4. Roninson IB. Tumor cell senescence in cancer treatment. Cancer Res. 2003;63(11):2705-2715.
5. Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell. 2005;120(4):513-522.
6. Hayfick L. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res. 1965;37:614-636.
7. Campisi J. d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol. 2007;8(9):729-740.
8. Bringold F, Serrano M. Tumor suppressors and oncogenes in cellular senescence. Exp Gerontol. 2000;35(3):317-329.
9. Chang BD, Broude EV, Dokmanovic M, et al. A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res. 1999;59(15): 3761-3767.
10. Gewirtz DA, Holt SE, Elmore LW. Accelerated senescence: an emerging role in tumor cell response to chemotherapy and radiation. Biochem Pharmacol. 2008;76(8):947-957.
11. Schwarze SR, Fu VX, Desotelle JA, Kenowski ML, Jarrard DF. The iden-tifcation of senescence-specifc genes during the induction of senescence in prostate cancer cells. Neoplasia. 2005;7(9):816-823.
12. Dimri GP, Lee X, Basile G, et al. A biomarker that identifes senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci \USA. 1995;92(20):9363-9367.
13. Ewald JA, Peters N, Desotelle JA, Hoffmann FM, Jarrard DF. A high-throughput method to identify novel senescence-inducing compounds. J Biomol Screen. 2009;14(7):853-858.
14. Michaloglou C, Vredeveld LC, Soengas MS, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature. 2005;436(7051): 720-724.
15. Collado M, Gil J, Efeyan A, et al. Tumour biology: senescence in prema-lignant tumours. Nature. 2005;436(7051):642.
16. Choi J, Shendrik I, Peacocke M, et al. Expression of senescence- associated beta-galactosidase in enlarged prostates from men with benign prostatic hyperplasia. Urology. 2000;56(1):160-166.
17. Majumder PK, Grisanzio C, O'Connell F, et al. A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell. 2008;14(2): 146-155.
18. Roberson RS, Kussick SJ, Vallieres E, Chen SY, Wu DY. Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers. Cancer Res. 2005;65(7):2795-2803.
19. Te Poele RH. Okorokov AL, Jardine L, Cummings J, Joel SP. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res. 2002;62(6):1876-1883.
20. Schmitt CA, Fridman JS, Yang M, et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell. 2002;109(3):335-346.
21. Xue W, Zender L, Miething C, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature. 2007; 445(7128):656-660.
22. Bunn CL, Tarrant GM. Limited lifespan in somatic cell hybrids and cybrids. Exp Cell Res. 1980;127(2):385-396.
23. Pereira-Smith OM, Smith JR. Expression of SV40 T antigen in fnite life-span hybrids of normal and SV40-transformed fbroblasts. Somatic Cell Genet. 1981;7(4):411-421.
24. Smith JR, Ning Y, Pereira-Smith OM. Why are transformed cells immortal? Is the process reversible? Am J Clin Nutr. 1992;55(6 suppl): 1215S-1221S.
25. Muggleton-Harris AL, DeSimone DW. Replicative potentials of various fusion products between WI-38 and SV40 transformed WI-38 cells and their components. Somatic Cell Genet. 1980;6(6):689-698.
26. Ravi RK, McMahon M, Yangang Z, et al. Raf-1-induced cell cycle arrest in LNCaP human prostate cancer cells. J Cell Biochem. 1999;72(4): 458-469.
27. Haq R, Brenton JD, Takahashi M, et al. Constitutive p38HOG mitogen-activated protein kinase activation induces permanent cell cycle arrest and senescence. Cancer Res. 2002;62(17):5076-5082.
28. Huck JJ, Zhang M, McDonald A, et al. MLN8054, an Inhibitor of Aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo. Mol Cancer Res. 2010;8(3):373-384.
29. Alimonti A, Nardella C, Chen Z, et al. A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. J Clin Invest. 2010;120(3):681-693.
30. Lin HK, Chen Z, Wang G, et al. Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature. 2010;464(7287):374-379.
31. Sugrue MM, Shin DY, Lee SW, Aaronson SA. Wild-type p53 triggers a rapid senescence program in human tumor cells lacking functional p53. Proc Natl Acad Sci \USA. 1997;94(18):9648-9653.
32. Jung MS, Yun J, Chae HD, et al. p53 and its homologues, p63 and p73, induce a replicative senescence through inactivation of NF-Y transcription factor. Oncogene. 2001;20(41):5818-5825.
33. Xu HJ, Zhou Y, Ji W, et al. Reexpression of the retinoblastoma protein in tumor cells induces senescence and telomerase inhibition. Oncogene. 1997;15(21):2589-2596.
34. Fang L, Igarashi M, Leung J, Sugrue MM, Lee SW, Aaronson SA. p21Waf1/Cip1/Sdi1 induces permanent growth arrest with markers of replicative senescence in human tumor cells lacking functional p53. Oncogene. 1999;18(18):2789-2797.
35. Dai CY, Enders GH. p16 INK4a can initiate an autonomous senescence program. Oncogene. 2000;19(13):1613-1622.
36. Tsugu A, Sakai K, Dirks PB, et al. Expression of p57(KIP2) potently blocks the growth of human astrocytomas and induces cell senescence. Am J Pathol. 2000;157(3):919-932.
37. Fuxe J, Akusjarvi G, Goike HM, Roos G, Collins VP, Pettersson RF. Adenovirus-mediated overexpression of p15INK4B inhibits human glioma cell growth, induces replicative senescence, and inhibits telomerase activity similarly to p16INK4A. Cell Growth Differ. 2000;11(7):373-384.
38. Lee S, Jeong SY, Lim WC, et al. Mitochondrial fssion and fusion mediators, hFis1 and OPA1, modulate cellular senescence. J Biol Chem. 2007;282(31):22977-22983.
39. Kuilman T, Michaloglou C, Vredeveld LC, et al. Oncogene-induced senescence relayed by an interleukin-dependent infammatory network. Cell. 2008;133(6):1019-1031.
40. Sprenger CC, Vail ME, Evans K, Simurdak J, Plymate SR. Over-expression of insulin-like growth factor binding protein-related protein-1(IGFBP-rP1/mac25) in the M12 prostate cancer cell line alters tumor growth by a delay in G1 and cyclin A associated apoptosis. Oncogene. 2002;21(1):140-147.
41. Wajapeyee N, Serra RW, Zhu X, Mahalingam M, Green MR. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell. 2008;132(3):363-374.
42. Ben-Porath I, Weinberg RA. The signals and pathways activating cellular senescence. Int J Biochem Cell Biol. 2005;37(5):961-976.
43. Beausejour CM, Krtolica A, Galimi F, et al. Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J. 2003;22(16): 4212-4222.
44. Chang BD, Swift ME, Shen M, Fang J, Broude EV, Roninson IB. Molecular determinants of terminal growth arrest induced in tumor cells by a chemotherapeutic agent. Proc Natl Acad Sci \USA. 2002;99(1):389-394.
45. Chang BD, Xuan Y, Broude EV, et al. Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene. 1999;18(34):4808-4818.
46. Schwarze SR, Shi Y, Fu VX, Watson PA, Jarrard DF. Role of cyclin-dependent kinase inhibitors in the growth arrest at senescence in human prostate epithelial and uroepithelial cells. Oncogene. 2001;20(57):8184-8192.
47. Guo X, Mills AA. p63, cellular senescence and tumor development. Cell Cycle. 2007;6(3):305-311.
48. Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene. 2005;24(17):2899-2908.
49. Keyes WM, Mills AA. p63: a new link between senescence and aging. Cell Cycle. 2006;5(3):260-265.
50. Schwarze SR, DePrimo SE, Grabert LM, Fu VX, Brooks JD, Jarrard DF. Novel pathways associated with bypassing cellular senescence in human prostate epithelial cells. J Biol Chem. 2002;277(17):14877-14883.
51. Untergasser G, Koch HB, Menssen A, Hermeking H. Characterization of epithelial senescence by serial analysis of gene expression: identifcation of genes potentially involved in prostate cancer. Cancer Res. 2002;62(21): 6255-6262.
52. Crescenzi E, Palumbo G, Brady HJ. Bcl-2 activates a programme of premature senescence in human carcinoma cells. Biochem J. 2003;375(pt 2): 263-274.
53. Larsson O, Scheele C, Liang Z, Moll J, Karlsson C, Wahlestedt C. Kinetics of senescence-associated changes of gene expression in an epithelial, temperature-sensitive SV40 large T antigen model. Cancer Res. 2004; 64(2):482-489.
54. Rebbaa A, Zheng X, Chou PM, Mirkin BL. Caspase inhibition switches doxorubicin-induced apoptosis to senescence. Oncogene. 2003;22(18): 2805-2811.
55. d'Adda di Fagagna F. Living on a break: cellular senescence as a DNA-damage response. Nat Rev Cancer. 2008;8(7):512-522.
56. Mallette FA, Gaumont-Leclerc MF, Ferbeyre G. The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence. Genes Dev. 2007;21(1):43-48. (Pubitemid 46089705)
57. Ota H, Tokunaga E, Chang K, et al. Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells. Oncogene. 2006;25(2):176-185.
58. Ishikawa F. Cellular senescence as a stress response. Cornea. 2006;25 (10 suppl 1):S3-S6.
59. Cozzi SJ, Parsons PG, Ogbourne SM, Pedley J, Boyle GM. Induction of senescence in diterpene ester-treated melanoma cells via protein kinase C-dependent hyperactivation of the mitogen-activated protein kinase pathway. Cancer Res. 2006;66(20):10083-10091.
60. Mason SA, Cozzi SJ, Pierce CJ, Pavey SJ, Parsons PG, Boyle GM. The induction of senescence-like growth arrest by protein kinase C-activating diterpene esters in solid tumor cells. Invest New Drugs. 2010;28(5):575-586.
61. Lu T, Finkel T. Free radicals and senescence. Exp Cell Res. 2008; 314(9):1918-1922.
62. Magda D, Lecane P, Wang Z, et al. Synthesis and anticancer properties of water-soluble zinc ionophores. Cancer Res. 2008;68(13):5318-5325.
63. Pospelova TV, Demidenko ZN, Bukreeva EI, Pospelov VA, Gudkov AV, Blagosklonny MV. Pseudo-DNA damage response in senescent cells. Cell Cycle. 2009;8(24):4112-4118.
64. Linge A, Weinhold K, Blasche R, Kasper M, Barth K. Downregulation of caveolin-1 affects bleomycin-induced growth arrest and cellular senescence in A549 cells. Int J Biochem Cell Biol. 2007;39(10):1964-1974.
65. Han Z, Wei W, Dunaway S, et al. Role of p21 in apoptosis and senescence of human colon cancer cells treated with camptothecin. J Biol Chem. 2002;277(19):17154-17160.
66. Berletch JB, Liu C, Love WK, Andrews LG, Katiyar SK, Tollefsbol TO. Epigenetic and genetic mechanisms contribute to telomerase inhibition by EGCG. J Cell Biochem. 2008;103(2):509-519.
67. Narath R, Ambros IM, Kowalska A, Bozsaky E, Boukamp P, Ambros PF. Induction of senescence in MYCN amplifed neuroblastoma cell lines by hydroxyurea. Genes Chromosomes Cancer. 2007;46(2):130-142.
68. Nakai R, Iida S, Takahashi T, et al. K858, a novel inhibitor of mitotic kinesin Eg5 and antitumor agent, induces cell death in cancer cells. Cancer Res. 2009;69(9):3901-3909.
69. Lee J, Lee I, Park C, Kang WK. Lovastatin-induced RhoA modulation and its effect on senescence in prostate cancer cells. Biochem Biophys Res Commun. 2006;339(3):748-754.
70. Coppe JP, Patil CK, Rodier F, et al. Senescence-associated secretory phe-notypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 2008;6(12):2853-2868.
71. Heiss EH, Schilder YD, Dirsch VM. Chronic treatment with resveratrol induces redox stress-and ataxia telangiectasia-mutated (ATM)-dependent senescence in p53-positive cancer cells. J Biol Chem. 2007;282(37): 26759-26766.
72. Bender JF, Grillo-Lopez AJ, Posada JG Jr. Diaziquone (AZQ). Invest New Drugs. 1983;1(1):71-84.
73. Bukowski RM, Fleming TR, Macdonald JS, Oishi N, Taylor SA, Baker LH. Evaluation of combination chemotherapy and phase II agents in pancreatic adenocarcinoma. A Southwest Oncology Group study. Cancer. 1993;71(2):322-325.
74. Ewald JA, Desotelle JA, Almassi N, Jarrard DF. Drug-induced senescence bystander proliferation in prostate cancer cells in vitro and in vivo. Br J Cancer. 2008;98(7):1244-1249.
75. Gerland LM, Peyrol S, Lallemand C, Branche R, Magaud JP, Ffrench M. Association of increased autophagic inclusions labeled for beta-galactosidase with fbroblastic aging. Exp Gerontol. 2003;38(8):887-895.
76. Petti C, Molla A, Vegetti C, Ferrone S, Anichini A, Sensi M. Coexpression of NRASQ61R and BRAFV600E in human melanoma cells activates senescence and increases susceptibility to cell-mediated cytotoxicity. Cancer Res. 2006;66(13):6503-6511.
77. Dirac AM, Bernards R. Reversal of senescence in mouse fbroblasts through lentiviral suppression of p53. J Biol Chem. 2003;278(14): 11731-11734.
78. Wang E. Senescent human fibroblasts resist programmed cell death, and failure to suppress bcl2 is involved. Cancer Res. 1995;55(11): 2284-2292.
79. Sasaki M, Kumazaki T, Takano H, Nishiyama M, Mitsui Y. Senescent cells are resistant to death despite low Bcl-2 level. Mech Ageing Dev. 2001;122(15):1695-1706.
80. Hampel B, Malisan F, Niederegger H, Testi R, Jansen-Durr P. Differential regulation of apoptotic cell death in senescent human cells. Exp Gerontol. 2004;39(11-12):1713-1721.
81. DeJesus V, Rios I, Davis C, et al. Induction of apoptosis in human repli-cative senescent fbroblasts. Exp Cell Res. 2002;274(1):92-99.
82. Krtolica A, Parrinello S, Lockett S, Desprez PY, Campisi J. Senescent fbroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc Natl Acad Sci \USA. 2001;98(21): 12072-12077.
83. Zhang H, Pan KH, Cohen SN. Senescence-specifc gene expression fingerprints reveal cell-type-dependent physical clustering of up-regulated chromosomal loci. Proc Natl Acad Sci \USA. 2003;100(6): 3251-3256.
84. Di X, Bright AT, Bellott R, et al. A chemotherapy-associated senescence bystander effect in breast cancer cells. Cancer Biol Ther. 2008;7(6): 864-872.
85. Untergasser G, Gander R, Rumpold H, Heinrich E, Plas E, Berger P. TGF-beta cytokines increase senescence-associated beta-galactosidase activity in human prostate basal cells by supporting differentiation processes, but not cellular senescence. Exp Gerontol. 2003;38(10): 1179-1188.
86. Lee BY, Han JA, Im JS, et al. Senescence-associated beta-galactosidase is lysosomal beta-galactosidase. Aging Cell. 2006;5(2):187-195.
87. Zhang R, Adams PD. Heterochromatin and its relationship to cell senescence and cancer therapy. Cell Cycle. 2007;6(7):784-789.
88. Acosta JC, O'Loghlen A, Banito A, et al. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell. 2008;133(6):1006-1018.
89. Zhang R, Chen W, Adams PD. Molecular dissection of formation of senescence-associated heterochromatin foci. Mol Cell Biol. 2007;27(6): 2343-2358.
90. Lawless C, Wang C, Jurk D, Merz A, Zglinicki TV, Passos JF. Quantitative assessment of markers for cell senescence. Exp Gerontol. 2010. [epub ahead of print].
91. Rastogi S, Joshi B, Dasgupta P, Morris M, Wright K, Chellappan S. Prohibitin facilitates cellular senescence by recruiting specifc corepressors to inhibit E2F target genes. Mol Cell Biol. 2006;26(11):4161-4171.
92. Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer. 2008;8(4):253-267.
93. Frescas D, Pagano M. Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer. 2008;8(6):438-449.
94. Aziz MH, Reagan-Shaw S, Wu J, Longley BJ, Ahmad N. Chemoprevention of skin cancer by grape constituent resveratrol: relevance to human disease? FASEB J. 2005;19(9):1193-1195.
95. Rusin M, Zajkowicz A, Butkiewicz D. Resveratrol induces senescence-like growth inhibition of U-2 OS cells associated with the instability of telomeric DNA and upregulation of BRCA1. Mech Ageing Dev. 2009; 130(8):528-537.
96. Halvorsen OJ. Molecular and prognostic markers in prostate cancer. A study of cell-cycle regulators, angiogenesis and candidate markers. APMIS Suppl. 2008;(123):5-62.
97. Bensalah K, Lotan Y, Karam JA, Shariat SF. New circulating bio-markers for prostate cancer. Prostate Cancer Prostatic Dis. 2008;11(2): 112-120.
98. Gatenby RA. A change of strategy in the war on cancer. Nature. 2009; 459(7246):508-509.